PGEN
Precigen, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +12.5% ·
share flow +30.0% ·
net new positions +11.1%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | +1 | 77.32M | $440.58M | +8 | −7 |
| Q1 2026 | 82 | +6 | 77.19M | $298.23M | +8 | −2 |
| Q4 2025 | 75 | -2 | 85.66M | $358.05M | — | −2 |
| Q3 2025 | 16 | +1 | 41.97M | $138.07M | +2 | −1 |
| Q2 2025 | 12 | +2 | 40.00M | $56.80M | +2 | — |
| Q1 2025 | 7 | 0 | 18.74M | $27.92M | +1 | −1 |
| Q4 2024 | 7 | -3 | 18.78M | $21.04M | — | −3 |
| Q3 2024 | 9 | +1 | 17.66M | $16.73M | +1 | — |
| Q2 2024 | 8 | — | 6.84M | $10.80M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 10.87M | New | $10.29M | 0.0% | New | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 3.25M | +4.8% | $3.08M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Renaissance Technologies ✦ | 1.60M | +35.3% | $1.52M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | D. E. Shaw & Co. ✦ | 1.22M | -29.6% | $1.15M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 383.00K | -8.8% | $362,738 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 169.50K | 0.0% | $161,000 | 0.0% | Held | 2 | SEC ↗ |
| 7 | Millennium Management ✦ | 119.06K | -16.1% | $112,762 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Two Sigma Investments ✦ | 43.16K | -10.7% | $40,876 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 15.89K | -68.2% | $15,052 | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $10.29M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 204 holders, 132.74M shares, $508.64M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director · 3.41K sh @ 7.23 · $24,662
Open-market sales (S)
Director · 185.00K sh · $1.38M
Officer · 15.34K sh · $115,065
Officer · 79.17K sh · $593,745
Officer · 34.66K sh · $259,935
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology